Company intelligence / Profile preview

Scottsdale Research Institute

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

SRI is currently leading the first government-funded FDA Phase 1/2 clinical trials on natural psilocybin mushrooms for patients with life-threatening illnesses. It has previously completed trials on cannabis flower for PTSD in veterans. Early results and ongoing studies aim to provide rigorous safety and efficacy data for natural plant medicines.

Therapeutic areas: OncologyNeurologyPsychiatryOther
Modalities: Small moleculeBotanical drugPsychedelic therapyPlant-derived therapy
Industry: Academic Hospital/University/Research

Partnerships

Alira Health

Beyond the preview

Go deeper on Scottsdale Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scottsdale Research Institute.

Explore the full profile